NCT00031343View on ClinicalTrials.gov

The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin

PHASE2CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

February 28, 2002

Study Completion Date

April 30, 2004

Conditions
HIV InfectionsHepatitis C
Interventions
DRUG

highly active antiretroviral therapy (HAART)

Trial Locations (1)

20892

National Institute of Allergy and Infectious Diseases (NIAID), Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00031343 - The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin | Biotech Hunter | Biotech Hunter